New cocktail aims to wipe out High-Risk prostate cancer before surgery

NCT ID NCT07027124

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of hormone therapy (Lupron), an androgen blocker (Darolutamide), and an immunotherapy (Pembrolizumab) given before and after prostate removal surgery in 40 men with high-risk prostate cancer. The goal is to see if this approach can reduce or eliminate cancer remaining after surgery. Participants must have specific genetic markers from a biopsy to join.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Darolutamide, Pembrolizumab, Leuprolide
What this could lead to: If successful, this combination could reduce residual cancer after surgery and improve long-term outcomes for high-risk prostate cancer patients.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply broadly. The combination may cause significant side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.